Rosetta Genomics Q4 Revenues Slide 62 Percent | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced revenues for the fourth quarter dropped to $45,000 from $119,000 a year ago, a 62 percent retreat.

For the three months ended Dec. 31, 2010, the company posted a net loss of $3.7 million, or $.21 per share, an 8 percent decline from a little more than $4 million, $.28 per share, from the fourth quarter of 2009.

On a non-GAAP basis, Rosetta saw a loss of $.20 per share, down from $.25 per share a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.